Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer

Abstract

Pancreatic cancer is an aggressive, drug-resistant disease; its first-line chemotherapeutic, gemcitabine, is only marginally effective. Intracellular depletion of glutathione, a major free-radical scavenger, has been associated with growth arrest and reduced drug resistance (chemosensitization) of cancer cells. In search of a new therapeutic approach for pancreatic cancer, we sought to determine whether specific inhibition of the plasma membrane xc-cystine transporter could lead to reduced uptake of cysteine, a key precursor of glutathione, and subsequent glutathione depletion. Sulfasalazine (approximately 0.2 mmol/L), an anti-inflammatory drug with potent x-inhibitory properties, markedly reduced l-[14C]-cystine uptake, glutathione levels, and growth and viability of human MIA PaCa-2 and PANC-1 pancreatic cancer cells in vitro. These effects were shown to result primarily from inhibi-tion of cystine uptake mediated by the xc-cystine transporter and not from inhibition of nuclear factor κB activation, another property of sulfasalazine. The efficacy of gemcitabine could be markedly enhanced by combination therapy with sulfasalazine both in vitro and in immunodeficient mice carrying xeno-grafts of the same cell lines. No major side effects were observed in vivo. The results of the present study suggest that the xc-transporter plays a major role in pancre-atic cancer by sustaining or enhancing glutathione biosynthesis, and as such, represents a potential therapeutic target. Sulfasalazine, a relatively non-toxic drug approved by the U.S. Food and Drug Administration, may, in combination with gemcit-abine, lead to more effective therapy of refractory pancreatic cancer. © 2010 Multimed Inc.